Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/30/2025

Insulin Intensification Plan Assessment

Insulin Dose Escalation Strategy

  • The American Diabetes Association recommends a 10-15% dose escalation approach for insulin titration, which aligns with the proposed insulin adjustments 1, 2
  • A basal insulin increase from current dose to 76 units twice daily represents appropriate aggressive titration for severe hyperglycemia with fasting glucose in the 240-331 mg/dL range 1, 2
  • The American Diabetes Association suggests that prandial insulin increase from 26 to 32 units per meal is appropriate given the marked hyperglycemia and need for postprandial coverage 1, 3
  • The plan for continued basal titration by 4 units every 3 days until fasting glucose reaches 80-130 mg/dL is guideline-concordant 2

Triglyceride Management Decision

  • The American College of Cardiology recommends monitoring triglycerides without increasing rosuvastatin, as severe hyperglycemia is the primary driver of elevated triglycerides, and improving glycemic control typically results in substantial triglyceride reduction 1
  • Reassess lipid panel 8-12 weeks after achieving glycemic control before considering statin dose adjustment 1

Monitoring Parameters and Safety

  • The American Diabetes Association recommends establishing a hypoglycemia management protocol: if blood glucose <70 mg/dL occurs, reduce the corresponding insulin component by 20-50% 4
  • The mildly low sodium and elevated osmolality are likely secondary to hyperglycemia and should improve with glucose control 5

Critical Pitfalls to Avoid

  • The American Diabetes Association advises against using sliding-scale insulin as monotherapy, as it is associated with poor outcomes 4
  • Do not aggressively target glucose <140 mg/dL in the acute phase; initial target of 140-180 mg/dL is safer and evidence-based 4
  • Ensure prandial insulin is timed appropriately with meals and adjusted based on carbohydrate intake 1, 6

Additional Metabolic Considerations

  • The mild hypoalbuminemia may affect insulin pharmacokinetics but does not require dose adjustment 5
  • Normal proBNP and preserved eGFR indicate no contraindications to aggressive insulin therapy 5
  • If the patient is on metformin, continue it as it improves insulin sensitivity and supports vitamin D absorption 1
  • Discontinue sulfonylureas if prescribed to minimize hypoglycemia risk during insulin intensification 1

Management of Severe Hyperglycemia Without DKA/HHS

Insulin Regimen Selection

  • The American College of Endocrinology recommends basal-bolus insulin as the guideline-recommended approach for severe hyperglycemia >300 mg/dL in non-critically ill patients 7, 8, 9
  • Continuous insulin infusion is reserved for critically ill patients requiring ICU-level care, severe DKA or HHS, and perioperative management during major surgery 7, 9, 10

Starting Insulin Dose for Insulin-Naïve Patients

  • Calculate total daily dose (TDD) at 0.3 U/kg per day for insulin-naïve patients with severe hyperglycemia, with 50% given as basal insulin and 50% as bolus insulin 7, 8, 11, 12
  • For an 80 kg patient, the total daily dose would be 24 units/day, with 12 units given as basal insulin and 12 units divided into three pre-meal doses of prandial insulin 9, 11

Monitoring Parameters

  • Point-of-care glucose testing should be performed every 4-6 hours initially, with increased frequency to every 1-2 hours if glucose >250 mg/dL or <70 mg/dL 7, 10
  • Target glucose range is 140-180 mg/dL for non-critically ill patients 10
  • Basic metabolic panel (sodium, potassium, glucose, creatinine) should be checked every 2-4 hours initially, with monitoring for hypokalemia and replacement of potassium if <4.0 mEq/L before starting insulin 10

Daily Insulin Adjustment

  • Insulin doses should be adjusted daily based on glucose patterns, with increases in basal insulin by 10-20% if fasting glucose is elevated, and increases in prandial dose by 10-20% if pre-meal or post-meal glucose is elevated 7, 8, 11
  • If hypoglycemia occurs, the insulin component responsible should be reduced by 20-50% 11

Critical Pitfalls to Avoid

  • Sliding-scale insulin alone should not be used as the sole regimen, as it is associated with poor glycemic control and increased complications 12, 10
  • Premixed insulin (70/30) should not be used in the hospital setting due to an unacceptably high rate of hypoglycemia 11, 13, 12
  • Glucose targets <140 mg/dL should not be aggressively pursued in the hospital, as this increases hypoglycemia risk without improving outcomes 13, 12
  • Metformin should not be continued in patients with hyponatremia and potential for evolving illness, due to increased risk of lactic acidosis 13